Serum bone biomarkers and oral/systemic bone loss in humans

We recently reported that subantimicrobial-dose doxycycline (sdd) significantly reduced serum bone-resorption biomarkers in subgroups of post-menopausal women. we hypothesize that changes in serum bone biomarkers are associated not only with systemic bone mineral density (bmd) changes,but also with alveolar bone changes over time. one hundred twenty-eight eligible post-menopausal women with periodontitis and systemic osteopenia were randomly assigned to receive sdd or placebo tablets twice daily for two years,adjunctive to periodontal maintenance. sera were analyzed for bone biomarkers. as expected,two-year changes in a serum bone biomarker were significantly associated with systemic bmd loss at the lumbar spine (osteocalcin,bone-turnover biomarker,p = 0.0002) and femoral neck (osteocalcin p = 0.0025). two-year changes in serum osteocalcin and serum pyridinoline-crosslink fragment of type i collagen (ictp; bone-resorption biomarker) were also significantly associated with alveolar bone density loss (p < 0.0001) and alveolar bone height loss (p = 0.0008),respectively. thus,we have shown that serum bone biomarkers are associated with not only systemic bmd loss,but with alveolar bone loss as well. clinical trial registration information: protocol registered at clinicaltrials.gov,nct00066027.abbreviations: bone mineral density (bmd),bone-specific alkaline phosphatase (bsap),computer-assisted densitometric image analysis (cadia),confidence interval (ci),deoxypyridinoline-containing degradation fragment of the c-terminal telopeptide region of type i collagen (ctx),coefficient of variation (cv),dual-energy x-ray absorptiometry (dxa),pyridinoline-crosslink-containing degradation fragment of the c-terminal telopeptide region of type i collagen (ictp),and subantimicrobial-dose doxycycline (sdd). © 2011 international & american associations for dental research.